The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection

Eleonora Castelletti, Sergio Lo Caputo, Louise Kuhn et al. · 2007

Read The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection by Eleonora Castelletti, Sergio Lo Caputo, Louise Kuhn et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0000969.txt.

Introduction

Eleonora Castelletti, Sergio Lo Caputo, Louise Kuhn and colleagues studied a mucosal signal chemical in HIV infection, in PLOS ONE in 2007. The chemical, CCL28 or MEC, draws antibody making cells into moist body linings. Those cells release IgA, the antibody that guards mucosal surfaces.

HIV specific IgA shows up both in infected people and in some exposed people who stay uninfected. The team analyzed the CCL28 circuit across infected, exposed and unexposed groups. Mucosal defense is where HIV usually enters, so its local signals matter. Work of this kind may help explain why a few exposed people resist infection.

Catalog record

CREATOREleonora Castelletti, Sergio Lo Caputo, Louise Kuhn et al.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000969

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection Authors: Eleonora Castelletti, Sergio Lo Caputo, Louise Kuhn, Manuela Borelli, Johanna Gajardo, Moses Sinkala, Daria Trabattoni, Chipepo Kankasa, Eleonora Lauri, Alberto Clivio, Luca Piacentini, Dorothy H. Bray, Grace M. Aldrovandi, Donald M. Thea, Francisco Veas, Manuela Nebuloni, Francesco Mazzotta, Mario Clerici Published: 2007, PLOS ONE DOI: 10.1371/journal.pone.0000969 ABSTRACT CCL28 (MEC) binds to CCR3 and CCR10 and recruits IgA-secreting plasma cells (IgA-ASC) in the mucosal lamina propria (MLP). Mucosal HIV-specific IgA are detected in HIV-infection and exposure. The CCL28 circuit was analyzed in HIV-infected and-exposed individuals and in HIV-unexposed controls; the effect of CCL28 administration on gastrointestinal MLP IgA-ASC was verified in a mouse model. CCL28 was augmented in breast milk (BM) plasma and saliva of HIV-infected and –exposed individuals; CCR3+ and CCR10+ B lymphocytes were increased in these same individuals. Additionally: 1) CCL28 concentration in BM was associated with longer survival in HIV vertically-infected children; and 2) gastro-intestinal mucosal IgA-ASC were significantly increased in VSV-immunized mice receiving CCL28. CCL28 mediates mucosal immunity in HIV exposure and infection. CCL28-including constructs should be considered in mucosal vaccines to prevent HIV infection of the gastro-intestinal MLP via modulation of IgA-ASC. INTRODUCTION Migration of IgA-secreting plasma cells into the mucosal lamina propria (MLP) was recently shown to be correlated with specific chemokines and chemokine receptors [1] – [13] . Thus, IgA-expressing plasma blasts and plasma cells (IgA-ASC) are characterized by a number of surface receptor proteins, including CCR9, CCR3, and CCR10, that are ligated by specific chemokines. In particular, it has been shown that CCR9 ligates the CC chemokine CCL25 (also known as thymus-expressed chemokine, or TECK) [4] , [10] , whereas both CCR10 and CCR3 bind a second CC chemokine named CCL28 (also known as mucosae-associated epithelial chemokine, or MEC) [1] , [5] , [10] , [12] . These interactions induce the migration and the recruitment of IgA-ASC in the MLP. CCL25 was shown in a mouse model to mostly attract a subpopulation of IgA-ASC associated with the small intestine [4] , [6] , [10] . CCL28 is more widely expressed and potently chemoattracts IgA-ASC originating from diverse mucosal lymphoid organs, as well as from intestinal and extra intestinal tissues, in every studied mucosal effector site-including the mammary and salivary glands-both in mice and humans [1] – [7] , [9] – [12] , [14] , [15] . Thus, the CCL28-CCR10/CCR3 circuit is considered to be a unifying system that plays a major role in the homing of plasma blasts and plasma cells at mucosal effector sites [3] , [5] , [13] . Interestingly, these chemotactic abilities are limited to IgA-ASC as the migration of neither IgM nor IgG ASC is stimulated by the CCL28-CCR10/CCR3 or the CCL25-CCR9 systems [1] – [13] . The CCL28-CCR10/CCR3 circuit is also endowed with other interesting peculiarities. Thus, CCL28 has a potent antimicrobial activity directed toward both Gram-positive and Gram-negative microorganisms [3] . Additionally, this chemokine is expressed by bone marrow stromal cells, suggesting that the interaction of CCL28 with CCR10+/CCR3+ B cells may contribute to the integration between the mucosal and the systemic immune responses [3] . High concentration of mucosal HIV-specific IgA have repeatedly been observed in HIV-infected individuals [16] – [19] and have also been suggested to characterize HIV sexually-exposed but uninfected individuals (Exposed Seronegatives or ESN) [20] – [23] . Thus, HIV-specific IgA were described to be present in saliva, cervico-vaginal secretions, and breast milk from both HIV-infected and ESN individuals in Europe, Asia and Africa by most [20] – [24] , but not all [25] authors. To investigate whether the presence of high concentrations of mucosal HIV-specific IgA could be explained by an upregulation of the chemokine circuits involved in mucosal homing of IgA-ASC, we first measured CCL25 and CCL28 in breast milk of a well-characterized cohort of HIV-infected breast feeding mothers from Zambia. Results showing a significantly augmented concentration of CCL28 in HIV IgA-positive milk encouraged us to analyze CCR3-, CCR9-, and CCR10-expressing cells as well as the mucosal concentration of CCL25 and CCL28 in ESN subjects and their HIV-infected partners. Results were compared to those seen in HIV-unexposed individuals. Finally, as it was recently shown that the privileged site of HIV replication during primary infection is the gastro-intestinal (GI) mucosa, and IgA could protect this mucosa, we verified whether the administration of CCL28 would result in a significant modulation of IgA in the GI tract using an animal model undergoing immunization with a VSV construct in the presence/absence of CCL28. Results herewith indicate a pivotal role for CCL28 in the modulation of mucosal immunity in HIV exposure and infection and suggest a usefulness of CCL28-containing adjuvants in the development of HIV vaccines. MATERIALS AND METHODS Breast milk samples were collected from 65 HIV-infected women enrolled in a breastfeeding study in Lusaka, Zambia [26] . The samples were selected to include 15 women who transmitted and 50 women who did not transmit HIV to their infant. Milk samples were collected by manual expression between 1 and 5 weeks post-partum. Milk samples from 9 uninfected Zambian women were included as controls. All women signed informed consent to participate. Blood samples and saliva were collected from 39 HIV-exposed but uninfected heterosexual partners of HIV-infected individuals (ESN)(27 females; 12 males). The inclusion criteria for the ESN was a history of multiple unprotected sexual episodes (with the same HIV-seropositive partner) for ≥4 years at the time of enrollment, with at least 8 episodes of at-risk intercourse within the 4 months before study entry, and an average of 30 reported unprotected sexual contacts per year (range 18 to >100). Forty age-matched HIV-infected patients (HIV+) and 30 age- and sex-matched healthy volunteer controls (HC), without any known risk factor for HIV-infection, were studied as well. All ESN and HIV-infected patients underwent in-depth clinical and laboratory evaluation that did not reveal any concomitant infectious or gynecologic problems. All individuals (ESN, HIV+, and HC) had been longitudinally followed for >4 years before the study by the Department of Obstetrics and Gynecology, Santa Maria Annunziata Hospital, Florence. This allowed us to exclude from the study ESN and HC in whom sexually transmitted diseases or any other pathology was reported during that time period. Each subject signed an informed consent form that was approved by the Ethical committee of the S. M. Annunziata Hospital. BREAST MILK PREPARATION All milk was processed within 4 hours of collection. Milk was centrifuged at 400g and the cell pellet removed. The supernatant and lipid portions were mixed together before aliquoting and were stored at −70°C until use. BLOOD SAMPLE COLLECTION AND SEPARATION OF PBMC Whole blood was collected by venipuncture in Vacutainer tubes containing EDTA (ethylenediaminetetraacetic acid) (Becton Dickinson, Rutherford, NJ). Peripheral blood mononuclear cells (PBMC) were separated on lymphocyte separation medium (Organon Teknica, Durham, NC) and washed twice in phosphate-buffered saline (PBS; Organon Teknica). The number of viable leukocytes was determined by trypan blue exclusion. All analyses were performed on freshly collected cells. IMMUNOPHENOTYPIC ANALYSIS Surface receptors were evaluated using 50 µl of EDTA peripheral blood. Cells were incubated for 30 min at 4°C with the following flourochrome-labeled mAbs: CD19- R-phycoerythrin-Cyanine 5 Tandem–PE-Cy5 (mouse IgG1 isotype, Beckman Coulter, Fullerton CA), CCR3-Phycoerythrin and CCR9-Fluorescein (mouse IgG2a

Read the complete text